Compare Amylx Pharmaceuticals Inc (AMLX) vs Chart Industries Inc (GTLS) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

GTLS trades at $209.87, up 0.13% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported $4.26B revenue in 2025 but missed EPS estimates for three consecutive quarters, with negative net income margin and ROE. Recent news highlights Baker Hughes' pending $13.6B acquisition, which secured EU antitrust approval in July 2026, providing a significant catalyst.

The stock's outlook is supported by strong analyst buy ratings (54%) and the acquisition premium, but risks include consistent earnings misses, profitability challenges, and integration execution. Valuation appears stretched with a P/E of 629.67, suggesting cautious optimism hinges on deal completion and margin improvement.